![](https://csdnimg.cn/release/download_crawler_static/87588092/bg1.jpg)
Guidelines
The British Society for Rheumatology Guideline for
the Management of Gout
Michelle Hui
1
, Alison Carr
2
, Stewart Cameron
3
, Graham Davenport
4
,
Michael Doherty
5
, Harry Forrester
4
, Wendy Jenkins
5
, Kelsey M. Jordan
6
,
Christian D. Mallen
4
, Thomas M. McDonald
7
, George Nuki
8
, Anthony Pywell
5
,
Weiya Zhang
5
and Edward Roddy
4,9
for the British Society for Rheumatology
Standards, Audit and Guidelines Working Group
Executive Summary
Scope and purpose of the guideline
Need for a revised management guideline
The British Society for Rheumatology/British Health
Professionals in Rheumatology guideline for the manage-
ment of gout was published in 2007 [1]. A revised
and updated guideline is now required because of the
availability of new pharmaceutical treatment options;
recent increases in the incidence, prevalence and severity
of gout [2]; continuing suboptimal management in
both primary and secondary care [2, 3]; and better under-
standing of patient and provider barriers to effective
care [4, 5].
Objectives of the guideline
To offer revised and updated, concise, patient-focused,
evidence-based, expert recommendations for the man-
agement of gout in the UK.
Target audience
To provide assistance to doctors and allied health profes-
sionals who treat and manage patients with gout in pri-
mary care and hospital practice.
Areas that the guideline does not cover
This guideline does not cover the diagnosis and
investigation of gout. This guideline has been reviewed
NICE has accredited the process used by the BSR to produce its
guidance for the management of gout. Accreditation is valid for 5 years
from 10 June 2013. More information on accreditation can be viewed
at www.nice.org.uk/accreditation. For full details on our accreditation
visit: www.nice.org.uk/accreditation.
1
Department of Rheumatology, Derby Teaching Hospitals NHS
Foundation Trust, Derby,
2
Hamell, 1st Floor Dome Building, The
Quadrant, Richmond, TW9 1DT UK,
3
Renal Medicine, Guy’s Campus,
Kings College London, London,
4
Research Institute for Primary Care and
Health Sciences, Keele University, Keele,
5
Academic Rheumatology,
University of Nottingham, Nottingham,
6
Rheumatology, Brighton and
Sussex University Hospitals NHS Trust, Brighton,
7
Medicines Monitoring
Unit, Ninewells Hospital and Medical School, Dundee,
8
Institute for
Genetics and Molecular Medicine, University of Edinburgh, Edinburgh
and
9
Haywood Academic Rheumatology Centre, Staffordshire and
Stoke-on-Trent Partnership NHS Trust, Stoke-on-Trent, UK
Correspondence to: Edward Roddy, Research Institute for Primary
Care and Health Sciences, Keele University, Keele, Staffordshire ST5
5BG, UK. E-mail: e.roddy@keele.ac.uk
Submitted 18 November 2016; revised version accepted
8 March 2017.
!
The Author 2017. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For Permissions, please email: journals.permissions@oup.com
RHEUMATOLOGY
Rheumatology 2017;56:10561059
doi:10.1093/rheumatology/kex150
Advance Access publication 26 May 2017
GUIDELINES
Downloaded from https://academic.oup.com/rheumatology/article/56/7/1056/3855178 by guest on 16 March 2023